
Axinat25 mcg/puf
ACME Laboratories Ltd.
Established (FDA-approved) uses Maintenance treatment of asthma in patients 4 years of age and older.
Salmeterol Xinafoate is not a rescue medicine. It does not relieve acute asthma or COPD symptoms and must not be used to treat acute bronchospasm or status asthmaticus. A separate fast-acting (short-acting beta-agonist) inhaler must always be available for acute symptoms.
| Indication | Population | Dose |
|---|---|---|
| Asthma (always with an ICS) | Adults and children 4 years and older | 1 inhalation twice daily (morning and evening), about 12 hours apart |
| Exercise-induced bronchospasm | Adults and children 4 years and older not already on a twice-daily LABA | 1 inhalation at least 30 minutes before exercise; do not repeat within 12 hours |
| COPD maintenance | Adults | 1 inhalation twice daily, about 12 hours apart |
Do not increase the frequency or number of inhalations beyond the prescribed dose. Maximum recommended dosing is twice daily; more frequent administration does not provide additional benefit and increases the risk of adverse effects. See Administration for device-specific technique.
Headache, influenza-like symptoms, nasal and sinus congestion, pharyngitis, rhinitis, tracheitis/bronchitis.
Cough, headache, musculoskeletal pain, throat irritation, viral upper respiratory infection.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.